Prediction of the Effects of Liraglutide on Kidney and Cardiovascular Outcomes Based on Short-Term Changes in Multiple Risk Markers

Prediction of the Effects of Liraglutide on Kidney and Cardiovascular Outcomes Based on Short-Term Changes in Multiple Risk Markers

Aims: The LEADER trial demonstrated that the glucagon-like peptide-1 receptor agonist (GLP1-RA) liraglutide reduces kidney and cardiovascular (CV) risk in patients with type 2 diabetes. We previously developed a Parameter Response Efficacy (PRE) score that translates multiple short-term risk marker...

Full description

Bibliographic Details
Main Authors: Sok Cin Tye, Sieta T. de Vries, Johannes F. E. Mann, Meir Schechter, Ofri Mosenzon, Petra Denig, Hiddo J. L. Heerspink
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-04-01
Series:Frontiers in Pharmacology
Subjects:
liraglutide
diabetes
risk markers
kidney outcomes
cardiovascular outcomes
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.786767/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.786767/full

Similar Items